Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Genuine Biotech (真实生物) Pre-IPO Tearsheet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Genuine Biotech is looking to raise at least US$100 million via a Hong Kong listing. The sole sponsor is CICC.</li>
<li>In our previous note, we briefly looked at the company’s fundamentals.</li>
<li>In this note, we analyzed the latest changes in the company and the challenges faced by the company.</li>
</ul>


Genuine Biotech is looking to raise at least US$100 million via a Hong Kong listing. The sole sponsor is CICC.
In our previous note, we briefly looked at the company’s fundamentals.
In this note, we analyzed the latest changes in the company and the challenges faced by the company.


Genuine Biotech (真实生物) Pre-IPO: Challenges Amid Restructuring